For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Food companies are capitalizing on the GLP-1 trend, offering high-protein, portion-controlled meals. But are they meeting ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

McKesson Corporation MCK is scheduled to report third-quarter fiscal 2025 results on Feb. 5, after market close. The company ...

People wanting to buy weight loss jabs online will face more stringent checks as part of a shake-up of UK pharmacy rules. The ...

While Cruz remains unranked in the deep 140-pound weight class, Ramos remains No. 8 ... TBA Record: 34-2-1, 24 KOs Last: L (UD12) Oleksandr Usyk, Dec. 21 Next: TBA Record: 22-2, 21 KOs Last ...